Fortis Healthcare Q4 FY26 Revenue Up 17.8% to ₹2,365 Cr; PAT Rises 44.2% to ₹271 Cr
Fortis Healthcare reported Q4 FY26 consolidated revenue of ₹2,365 Cr, up 17.8% YoY. PAT increased 44.2% to ₹271 Cr. For FY26, revenue was ₹9,128 Cr (up 17.3%) and PAT was ₹1,064 Cr (up 31.5%). The Board recommended a dividend of ₹1 per share.
The significant double-digit growth in key financial metrics and the declaration of a dividend are material positive developments that are likely to impact investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax for both the quarter and the full financial year. The recommended dividend also indicates a positive financial outlook.
Fortis Healthcare Limited announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026.
For the fourth quarter of FY26, consolidated revenues stood at ₹2,365 crore, marking a significant 17.8% increase compared to ₹2,007 crore in Q4 FY25. Operating EBITDA also saw a robust rise of 22.2% to ₹531 crore from ₹435 crore in the same period last year, with margins improving to 22.5% from 21.7%. Profit After Tax (PAT) surged by 44.2% to ₹271 crore, up from ₹188 crore in Q4 FY25. The company's hospital business revenue grew by 19.0% to ₹2,023 crore, while the diagnostics business reported gross revenues of ₹387 crore, an 11.1% increase.
For the full financial year FY26, consolidated revenues reached ₹9,128 crore, up 17.3% from ₹7,783 crore in FY25. Operating EBITDA increased by 31.3% to ₹2,085 crore, with margins expanding to 22.8% from 20.4%. PAT for FY26 grew by 31.5% to ₹1,064 crore from ₹809 crore in FY25. The hospital business reported FY26 revenue of ₹7,773 crore (up 19.1%), and the diagnostics business reported gross revenues of ₹1,527 crore (up 8.5%).
The Board of Directors recommended a dividend of ₹1 per share (10% of face value), subject to shareholder approval. The company also highlighted strategic acquisitions and expansions, including the acquisition of People Tree Hospital in Bengaluru, Shrimann Hospital in Punjab, and a long-term lease for a hospital in Greater Noida. Dr. Ashutosh Raghuvanshi, MD and CEO, commented on the steady business performance and continued investment in augmenting medical equipment and technology.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.